Updates to the Management of Cutaneous Melanoma
Despite recent advances in immunotherapies and targeted therapies for patients with advanced melanoma, treatment options are at times limited by the availability of reliable molecular markers, development of drug resistance, and the need for better early diagnosis. An overview of current challenges facing this patient population, as well as an in-depth analysis of treatment modalities, will benefit clinicians in selecting treatment options for patients with melanoma.
Category
  • Melanoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates to the Management of Endometrial Cancer
Comprehensive knowledge in this topic will guide practitioners in providing appropriate treatment to improve patient outcomes.
Category
  • Gynecologic Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status
While the prognosis for patients with squamous and basal cell skin cancer is generally good, current treatment recommendations are limited by the risk status classifications and associated available treatment options. There are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of these disease features is crucial to identifying such patients and performing the appropriate treatment, especially as new regimens become available.
Category
  • Skin Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation
It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Pages